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Abstract
Background: The current exploratory analysis was performed to evaluate the efficacy and safety of everolimus for
treatment of human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer in the Asian
subset of patients in the BOLERO-1 trial.
Methods: Postmenopausal women with HER2+ advanced breast cancer, who had not received systemic therapy
for advanced disease, were randomized 2:1 to receive everolimus or placebo, plus trastuzumab and paclitaxel. The
two primary end points were investigator-assessed progression-free survival (PFS) in the full population and in the
hormone receptor-negative (HR–) subpopulation. Secondary end points included assessment of the objective
response rate, the clinical benefit rate, and safety.
Results: In the Asian subset, median PFS was similar in the everolimus (n = 198) and placebo (n = 105) arms in the
full analysis set (hazard ratio = 0.82 (95% CI 0.61–1.11)). In the HR– subpopulation, everolimus prolonged median
PFS by 10.97 months vs placebo (25.46 vs 14.49 months; hazard ratio = 0.48 (95% CI 0.29–0.79)). In the everolimus
arm of the Asian subset, the most common adverse events of any grade were stomatitis (62.2%), diarrhea (48.0%),
rash (43.4%) and neutropenia (42.3%). Neutropenia (grade 3: 27.6%; grade 4: 4.6%) and decreased neutrophil count
(grade 3: 11.2%; grade 4: 3.6%) were the most frequent grade 3/4 adverse events. Serious adverse events included
pneumonia (5.1%), pneumonitis (3.1%), and interstitial lung disease (3.1%). There were three deaths (1.5%) during
treatment in the everolimus arm vs none in the placebo arm.
Conclusions: The efficacy and safety of everolimus plus trastuzumab and paclitaxel as first-line treatment for HER2+
advanced breast cancer in the Asian subset was consistent with that reported previously in the overall population.
Trial registration: ClinicalTrials.gov, NCT00876395. Registered on 2 April 2009.
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Background
Human epidermal growth factor receptor-2 (HER2)
overexpression has been reported in approximately
20–25% of breast cancers and is historically associ-
ated with poor outcomes [1, 2]. The advent of tras-
tuzumab, an HER2-targeted agent, has dramatically
improved outcomes in patients with HER2-positive
(HER2+) breast cancer [3]. Apart from trastuzumab,
several other newer HER2-targeted agents (lapatinib,
pertuzumab and trastuzumab emtansine (T-DM1))
have also demonstrated clinical benefit in patients with
HER2+ breast cancer [4–8]. However, resistance to HER2-
targeted therapies (both de novo and acquired) remains a
clinical challenge and warrants exploration of additional
treatment options, which could improve outcomes in
patients with HER2+ advanced breast cancer [9, 10].
The phosphoinositide 3 kinase (PI3K)/Akt/mammalian
(or mechanistic) target of rapamycin (mTOR) pathway
has been implicated in the development of resistance to
HER2-targeted therapies due to its crosstalk with HER2
signaling [11, 12]. In preclinical and xenograft studies,
everolimus, an mTOR inhibitor, sensitized phosphatase
and tensin homolog (PTEN)-null tumors to trastuzumab
[13, 14]. These data suggest a potential role for the com-
bination of everolimus and trastuzumab in the treatment
of HER2+ breast cancer.
The efficacy and safety of everolimus in combination
with trastuzumab plus chemotherapy has been evaluated
in two phase-III clinical trials, BOLERO-1 and
BOLERO-3 [15, 16]. In BOLERO-1, everolimus plus
trastuzumab and paclitaxel as first-line therapy for
HER2+ advanced breast cancer did not improve
progression-free survival (PFS) vs trastuzumab and pac-
litaxel alone in the full population (median PFS
14.95 months vs 14.49 months; hazard ratio = 0.89 (95%
confidence interval (CI) 0.73–1.08); P = 0.1166); however,
there was 7.2-month improvement in PFS in the everoli-
mus arm in the hormone receptor-negative (HR–) sub-
population (median PFS 20.27 months vs 13.08 months;
hazard ratio = 0.66 (95% CI 0.48–0.91); P = 0.0049),
which was close to, but did not cross, the protocol-
specified significance threshold of P = 0.0044 by a small
margin [16]. In BOLERO-3, the addition of everolimus
to trastuzumab and vinorelbine significantly prolonged
PFS compared to trastuzumab and vinorelbine alone in
patients with HER2+ advanced breast cancer progressing
on prior trastuzumab and taxane (median PFS
7.0 months vs 5.78 months; hazard ratio = 0.78 (95% CI
0.65–0.95)); P = 0.0067) [15].
Available evidence from several recent trials suggests
that pharmacokinetics and pharmacodynamics of drugs
may vary across ethnicities [17–22]. As a result, clinical
outcomes and safety profiles in patients from one ethnic
background could be different from those in another.
For example, the incidence of interstitial lung disease
was higher in Asian patients treated with gefitinib
monotherapy compared to patients from other ethnic
backgrounds [21]. Similarly, the incidence of grade 1 or
2 interstitial lung disease was higher in an Asian subset
of patients in BOLERO-2, although the trial population
was different (HR+, HER2– advanced breast cancer pro-
gressing on prior nonsteroidal aromatase inhibitors
treated with everolimus plus exemestane) [19]. In
CLEOPATRA, a phase-III trial of pertuzumab in com-
bination with trastuzumab and docetaxel in patients
with HER2+ advanced breast cancer, the overall
incidence of adverse events was higher in Asian vs non-
Asian patients [17]. These data highlight the importance
of evaluating the clinical benefit of treatment regimens
in individual ethnic subpopulations.
The current exploratory analysis of the BOLERO-1
trial evaluated the efficacy and safety of everolimus in
combination with trastuzumab and paclitaxel in Asian
patients with HER2+ advanced breast cancer.
Methods
Study design and participants
BOLERO-1 was a phase III, multicenter, international,
randomized, double-blind, placebo-controlled study and
has been described previously [16]. Briefly, women aged
≥18 years with HER2+ metastatic or locally recurrent in-
vasive breast cancer were eligible [16]. Patients with no
prior trastuzumab or with (neo)adjuvant trastuzumab
and/or chemotherapy discontinued >12 months from
randomization were eligible. Patients were not eligible
for the trial if they had received systemic therapy for
advanced disease, except for endocrine therapy. All
patients provided written informed consent. Patients
were categorized as Asian or non-Asian based on race.
The study was performed in accordance with the Good
Clinical Practice guidelines and the Declaration of
Helsinki. The study protocol was approved by an inde-
pendent ethics committee or by the institutional review
boards of the participating centers.
Procedures
BOLERO-1 procedures have been described in detail
previously [16]. Briefly, patients were randomized 2:1 to
receive everolimus (10 mg/day) or placebo in combin-
ation with trastuzumab and paclitaxel. Randomization
was stratified by the presence of visceral metastases
and prior (neo)adjuvant trastuzumab treatment. Treat-
ment continued until disease progression, development
of unacceptable toxicity, or consent withdrawal. Tumor
assessments were performed 28 days prior to start of
therapy (baseline assessment) and every 8 weeks after
treatment initiation until disease progression based on
the response evaluation criteria in solid tumors
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(RECIST). Efficacy end points were analyzed based on
investigator assessments, and additional supportive
analyses were conducted based on the central assess-
ments. Adverse events were graded as per the National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCI-CTCAE) version 3.0.
Study end points
The study had two primary objectives: (1) investigator-
assessed PFS in the full population and (2) investigator-
assessed PFS in the HR– subpopulation. Secondary end
points included assessment of the objective response
rate (ORR), the clinical benefit rate (CBR), and safety.
Statistical analyses
Statistical analysis of BOLERO-1 has been described
previously [16]. For analysis of the Asian and non-
Asian subsets, a non-stratified Cox regression model
was used to estimate the hazard ratio for PFS and the
95% CI.
Results
Patient characteristics
A total of 719 patients were enrolled in the study
between 10 September 2009 and 16 December 2012
[16]. Of these, 303 patients were Asian; 198 patients
were randomized to the everolimus arms and 105
patients to the placebo arm. All 303 Asian patients
were included in the efficacy analysis and 300 were
included in the safety analysis. The baseline and
disease characteristics were generally similar in the
Asian and the non-Asian subset and were well-
balanced between the two treatment arms. The
majority of the Asian patients were of Chinese ethni-
city (73.2%), followed by patients of Japanese ethnicity
(13.6%). A larger proportion of Asian patients in the
everolimus arm had an Eastern Cooperative Oncology
Group (ECOG) performance status = 0 compared to
non-Asian patients (61.1% vs 55.7%) (Table 1).
At the time of data cutoff (30 May 2014), 256 pa-
tients (84.5%) in the Asian subset discontinued treat-
ment; 44 patients continued treatment (30 patients
(15.2%) in the everolimus arm and 14 patients
(13.3%) in the placebo arm). The most common
reason for discontinuation was disease progression
occurring in 112 patients (56.6%) in the everolimus
arm and 71 patients (67.6%) in the placebo arm of
the Asian subset. There was more discontinuation
due to disease progression in the everolimus arm of
the Asian subset (56.6%) vs the non-Asian subset
(47.2%). Similarly, more Asian patients in the everoli-
mus arm discontinued due to consent withdrawal
compared to the non-Asian patients (14.6% vs 11.7%).
There was less discontinuation due to adverse events
in the everolimus arm in the Asian subset (10.1%) vs
the non-Asian subset (13.8%) (Fig. 1).
The number of patients requiring dose reductions/in-
terruptions was larger in the Asian subset than in the
non-Asian subset, in both the everolimus and placebo
arms (88.3% vs 84.4% in the everolimus arm and 79.8%
vs 68.7% in the placebo arm). The most common cause
of dose reduction/interruption was adverse events and
this was similar in the everolimus arms of Asian and the
non-Asian subset (95.4% vs 95.3%). More patients in the
everolimus arm of the Asian subset experienced dose
reductions/interruption due to dosing error compared to
the non-Asian subset (48.0% vs 36.5%) (Additional file 1:
Table S1).
Dose intensity and exposure
The relative dose intensity of everolimus was lower in
the Asian subset compared to the non-Asian subset (me-
dian 0.51 vs 0.57). The dose intensity of paclitaxel was
also lower in the Asian subset compared to the non-
Asian subset, in both the everolimus and placebo arms.
Trastuzumab dose intensity was similar across both sub-
sets in the everolimus and placebo arms. The duration
of exposure of everolimus was longer in the Asian subset
compared to the non-Asian subset (median, 42.1 weeks
vs 40.0 weeks). Similarly, the duration of exposure of
trastuzumab and paclitaxel was also longer in the Asian
subset compared to the non-Asian subset, in both the
everolimus and placebo arms. In the HR– subpopula-
tion, the everolimus dose intensity was numerically
lower in the Asian than in the non-Asian subset (median
0.50 vs 0.61), and the duration of everolimus treatment
was similar in the Asian subset (45.8 weeks vs
44.7 weeks) (Table 2).
Efficacy
In both the Asian and non-Asian subsets, the addition
of everolimus to trastuzumab and paclitaxel did not
improve PFS compared to placebo plus trastuzumab and
paclitaxel in the full analysis set, but did prolong PFS in
the respective HR– subpopulations (Figs. 2 and 3). The
median PFS in the everolimus arm compared to the
placebo arm in the Asian subset was 18.40 months vs
18.20 months (hazard ratio = 0.82; 95% CI 0.61–1.11)
(Fig. 1). In the non-Asian subset, the median PFS in the
everolimus compared to the placebo arm was
14.55 months vs 11.60 months (hazard ratio = 0.93; 95%
CI 0.72–1.21) (Fig. 2).
In the HR– Asian subset, median PFS in the
everolimus arm was 25.46 months compared to
14.49 months in the placebo arm (hazard ratio = 0.48;
95% CI 0.29–0.79) translating into a 10.97 months
improvement in the median PFS. In the HR– subpop-
ulation of the non-Asian subset, median PFS in the
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everolimus arm was 16.20 months compared to
12.29 months in the placebo arm (hazard ratio = 0.76;
95% CI 0.51–1.15) (Fig. 3).
In the Asian subset, the ORR and CBR were similar in
the everolimus and placebo arms (ORR 69.2% vs 69.5%;
CBR 80.8% vs 82.9%) (Additional file 1: Table S2). In the
non-Asian subset, both the ORR and CBR were lower in the
everolimus arm compared to the placebo arm (ORR 65.6%
vs 68.7%; CBR 72.3% vs 79.9%). Both the ORR and the CBR
were higher in the everolimus arm of the Asian subset than
in the non-Asian subset (Additional file 1: Table S3).
PFS was also analyzed in several predefined subgroups
(Fig. 4). In the Asian subset, there was a trend towards a
greater PFS benefit in the everolimus arm compared to
Table 1 Baseline and treatment characteristics of the Asian and non-Asian subsets (full analysis set)
Characteristic Asian Non-Asian
EVE + TRAS + PAC PBO + TRAS + PAC EVE + TRAS + PAC PBO + TRAS + PAC
n = 198 n = 105 n = 282 n = 134
Median age, years (range) 53.0 (23–75) 51.0 (29–82) 55.0 (26–86) 52.0 (19–77)
Race, n (%)
Asian 198 (100%) 105 (100%) 0 0
Black 0 0 26 (9.2) 12 (9.0)
White 0 0 214 (75.9) 97 (72.4)
Native American 0 0 3 (1.1) 0
Other non-Asian 0 0 39 (13.8) 25 (18.7)
Ethnicity, n (%)
Chinese 145 (73.2) 75 (71.4) 0 0
Indiana 1 (0.5%) 0 0 0
Japanese 27 (13.6) 15 (14.3) 0 0
Other Asian 25 (12.6) 15 (14.3) 0 0
Hispanic/Latino 0 0 78 (27.7) 34 (25.4)
Other non-Asian 0 0 204 (72.3) 100 (74.6)
Current disease status, n (%)
Locally advanced 10 (5.1) 7 (6.7) 24 (8.5) 9 (6.7)
Metastatic 188 (94.9) 98 (93.3) 258 (91.5) 125 (93.3)
Site of metastasis, n (%)
Visceral 139 (70.2) 65 (61.9) 199 (70.6) 104 (77.6)
Lung 91 (46.0) 43 (41.0) 126 (44.7) 60 (44.8)
Liver 66 (33.3) 36 (34.3) 111 (39.4) 74 (55.2)
Lung and liver 27 (13.6) 17 (16.2) 45 (16.0) 34 (25.4)
Bone 85 (42.9) 54 (51.4) 125 (44.3) 63 (47.0)
Bone only 9 (4.5) 5 (4.8) 11 (3.9) 2 (1.5)
Others 142 (71.7) 77 (73.3) 196 (69.5) 99 (73.9)
ECOG PS, n (%)
0 121 (61.1) 64 (61.0) 157 (55.7) 84 (62.7)
1 77 (38.9) 41 (39.0) 125 (44.3) 50 (37.3)
ER and PgR status, n (%)
ER and PgR negative (HR–) 85 (42.9) 47 (44.8) 123 (43.6) 56 (41.8)
ER and PgR negative (HR+) 112 (56.6) 57 (54.3) 159 (56.4) 78 (58.2)
Not assessable 0 1 (1.0) 0 0
Missing 1 (0.5) 0 0 0
aIndian subcontinent. ECOG PS Eastern Cooperative Oncology Group performance status, ER estrogen receptor, EVE everolimus, HR hormone receptor, PAC
paclitaxel, PBO placebo, PgR progesterone receptor, TRAS trastuzumab
Toi et al. Breast Cancer Research  (2017) 19:47 Page 4 of 13
the placebo arm in patients treated with prior (neo)-
adjuvant taxane (n = 108) (hazard ratio = 0.61; 95% CI
0.37-.0.99), patients with HR− disease (n = 132) (haz-
ard ratio = 0.48; 95% CI 0.29–0.79), patients with
disease relapse <24 months after diagnosis (n = 153)
(hazard ratio = 0.64; 95% CI 0.42–0.98) and in patients
without bone involvement (n = 163) (hazard ratio =
0.63; 95% CI 0.40–0.98). The PFS benefit from evero-
limus in patients with visceral metastases (hazard
ratio = 0.78; 95% CI 0.54–1.12) and in patients with-
out visceral metastases (hazard ratio = 0.84; 95% CI
0.49–1.44) was similar to that in the overall popula-
tion (Fig. 4). In general, more subgroups of Asian
patients had PFS benefit with everolimus compared to
the subgroups of non-Asian patients (Fig. 4).
Safety
In the everolimus arm of the Asian subset, the most
common non-hematologic adverse events of any grade
were stomatitis (62.2%), diarrhea (48.0%), rash (43.4%),
and alopecia (41.3%); the most common hematologic
adverse events were neutropenia (42.3%), neutrophil
count decrease (21.9%), and leukopenia (20.4%) (Table 3).
In the everolimus arm, the incidence of pneumonia was
12.2% in the Asian subset compared to 7.6% in the non-
Asian subset. The incidence of pneumonitis was 12.2%
in the Asian subset compared to 19.2% in the non-Asian
subset. The most frequent grade 3 and grade 4 adverse
events in the everolimus arm of Asian subset were neu-
tropenia (grade 3: 27.6%; grade 4: 4.6%) and decreased
neutrophil count (grade 3: 11.2%; grade 4: 3.6%)
(Table 3). In general, hematologic adverse events oc-
curred more frequently in the Asian subset than in the
non-Asian subset in both the everolimus and placebo
arms. The non-hematologic adverse events that occurred
more frequently in both arms of the Asian subset than
in they did in the non-Asian subset included increased
alanine aminotransferase, nasopharyngitis, hypoesthesia,
myalgia, mouth ulceration, and neurotoxicity (Table 3).
Overall, more Asian patients (34.3%) than non-Asian pa-
tients (5.9%) received granulocyte-colony stimulating
factor (G-CSF). In the everolimus arm, 36.7% of Asian
patients compared to 4.4% of non-Asian patients
received G-CSF (Additional file 1: Table S3). The per-
centage of patients receiving G-CSF at each cycle of the
study treatment was greater in the Asian subset com-
pared to the non-Asian subset.
The most common adverse events leading to treat-
ment discontinuation in the Asian subset were neuro-
toxicity (14.8% in the everolimus arm vs 17.3% in the
placebo arm) and hypoesthesia (8.7% in the everoli-
mus arm vs 7.7% in the placebo arm) (Additional file
1: Table S4). None of the patients in the non-Asian
subset discontinued treatment due to neurotoxicity or
hypoesthesia. Discontinuation of treatment due to sto-
matitis was more frequent in the Asian subset (5.6%)
than in the non-Asian subset (2.9%), and fewer Asian
patients (4.1%) discontinued treatment due to
pneumonitis compared to non-Asian patients (6.9%)
(Additional file 1: Table S4).
Fig. 1 Consolidated standards of reporting trials (CONSORT) flowchart. *Does not include the on-treatment deaths until 28 days of follow-up
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Fig. 2 Kaplan-Meier curves for progression-free survival in the full analysis set (investigator assessment). a Asian subset. b Non-Asian subset
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Fig. 3 Kaplan-Meier curves for progression-free survival in the hormone receptor-negative subpopulation (investigator assessment). a Asian subset.
b Non-Asian subset
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Fig. 4 (See legend on next page.)
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The most frequent serious adverse events in the
everolimus arm of the Asian subset were pneumonia
(5.1%), pneumonitis (3.1%), and interstitial lung disease
(3.1%) (Additional file 1: Table S5). The most frequent
serious adverse events in the everolimus arm of the
non-Asian subset were pneumonitis (5.4%), stomatitis
(3.6%), and dyspnea (3.6%) (Additional file 1: Table S5).
The incidence of serious pneumonia (3.3%) and inter-
stitial lung disease (0.4%) was lower in the non-Asian
subset; however, the incidence of serious pneumonitis
(5.4%), stomatitis, and dyspnea (3.6%) was higher in the
non-Asian subset (Additional file 1: Table S5). There
were three deaths on treatment (1.5%) in the everoli-
mus arm of the Asian subset, one due to disease
progression, one to pneumonia, and one to sepsis.
There were 19 deaths (6.9%) in the everolimus arm of
the non-Asian subset; there were no deaths on treat-
ment in the placebo arm of the Asian subset, whereas
there were 2 deaths (1.5%) in the non-Asian subset
(Additional file 1: Table S6).
Discussion
Addition of everolimus to trastuzumab and paclitaxel as
first-line treatment in the advanced setting for patients
with HER2+ did not have PFS benefit in the Asian
subset although median PFS was prolonged in the HR–
subgroup compared to the placebo arm. The safety pro-
file of everolimus was generally similar in the Asian and
non-Asian subsets, and no new safety signals were iden-
tified. These data suggest that the efficacy and safety of
everolimus in combination with trastuzumab and pacli-
taxel as first-line treatment for HER2+ advanced breast
cancer in Asian patients was consistent with that in the
overall population in BOLERO-1 [16].
Some differences were noted between the Asian and
non-Asian subsets in terms of efficacy, adverse event
profile, and drug exposure, which could be attributed
to the inherent differences in ethnic background.
Among Asian, non-Asian, and the overall population,
the difference in median PFS in the HR-negative sub-
population was largest in the Asian subset with a
hazard ratio of 0.48 (95% CI 0.29–0.79), while in the
non-Asian subset, the hazard ratio was 0.76 (95% CI
0.51–1.15). In subgroup analyses, in the Asian
subpopulation, there was a trend towards a greater
PFS benefit in those patients who had previously been
treated with (neo)adjuvant taxane, had HR– disease,
had disease relapse <24 months after diagnosis, or
had no bone involvement, and who were receiving
receiving everolimus. A potential explanation could be
the longer duration of exposure to everolimus in the
Asian subset. The lower dose intensity of everolimus
in the Asian subset may have allowed patients to
receive treatment for a longer duration. The duration
of exposure to trastuzumab and paclitaxel was also
longer in the Asian subset and could have contrib-
uted to the longer PFS.
The incidence of hematologic adverse events, notably
decreased neutrophil count and leukopenia, was higher
in the Asian subset (in both the everolimus and placebo
arms) than in the non-Asian subset. This is consistent
with the higher incidence of hematologic adverse events
reported in previous studies of Asian patients with solid
tumors treated with targeted therapy and/or chemother-
apy [23–26] and could be attributed to the inherent
ethnic differences between Asian and non-Asian subsets.
Hematologic adverse events were more frequently man-
aged using G-CSF among the Asian subset. In general,
the percentage of patients receiving G-CSF decreased
with each cycle of study treatment.
Some of the limitations of the present analysis
include the exploratory nature and the relatively small
number of patients and events, especially in the sub-
group analyses. However, the pronounced PFS benefit
with everolimus in the HR– subgroup of the Asian
subset warrants further exploration. An evaluation of
the benefit of longer duration of treatment with
everolimus, with appropriate dose modification based
on the ethnic background, is also warranted. Examin-
ing the underlying risk factors and molecular/physio-
logical differences between Asian and non-Asian
patients may help explain the higher incidence of
hematologic adverse events reported here and in
other trials.
Conclusions
The efficacy and safety of everolimus plus trastuzu-
mab and paclitaxel as first-line treatment for HER2+
advanced breast cancer in the Asian subset was
consistent with that reported previously in the overall
(See figure on previous page.)
Fig. 4 Forest plot of progression-free survival subgroup analysis (investigator assessment). a Asian subset. b Non-Asian subset. The hazard ratios
were obtained using a non-stratified Cox proportional hazard model. *The majority of patients were from Asia. Due to small numbers, region is
not displayed within Fig. 4. CRF case report form, ECOG PS Eastern Cooperative Oncology Group performance status, adj adjuvant, diag. diagnosis,
EU Europe, IWRS interactive voice and web response system, LA Latin America, NA North America, neo-adj neoadjuvant, recur recurrence
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Table 3 Adverse events in the safety set with incidence ≥15% in the everolimus arm of he Asian or non-Asian subset
Adverse event, % Asian Non-Asian
EVE + TRAS + PAC PBO + TRAS + PAC EVE + TRAS + PAC PBO + TRAS + PAC
n = 196 n = 104 n = 276 n = 134
Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4
Stomatitis 62.2 6.6 0.0 31.7 0.0 0.0 69.6 16.7 0.0 32.8 2.2 0.0
Diarrhea 48.0 6.1 0.0 40.4 3.8 0.0 62.7 11.2 0.0 51.5 4.5 0.0
Rash 43.4 1.0 0.0 24.0 1.0 0.0 38.0 0.4 0.0 17.9 0.0 0.0
Neutropenia 42.3 27.6 4.6 26.9 17.3 3.8 34.1 16.7 2.9 23.1 5.2 4.5
Alopecia 41.3 0.0 0.0 41.3 0.0 0.0 50.7 0.4 0.0 61.2 0.0 0.0
Pyrexia 39.8 0.5 0.0 26.0 1.0 0.0 38.4 2.2 0.0 26.9 1.5 0.0
Cough 38.3 0.5 0.0 35.6 0.0 0.0 41.3 0.4 0.0 30.6 1.5 0.0
Fatigue 33.2 3.1 0.0 29.8 1.9 0.0 36.6 6.2 0.0 40.3 3.0 0.0
Epistaxis 29.1 0.0 0.0 10.6 0.0 0.0 36.2 0.0 0.0 23.1 0.0 0.0
Edema peripheral 28.6 0.0 0.0 17.3 1.0 0.0 36.2 1.4 0.0 29.9 0.0 0.0
ALT increased 28.1 5.1 0.0 26.9 6.7 0.0 15.6 6.5 0.0 11.9 3.0 0.7
Nasopharyngitis 27.0 0.0 0.0 30.8 1.9 0.0 12.7 0.0 0.0 11.2 0.0 0.0
Nausea 26.0 0.5 0.0 25.0 1.9 0.0 37.3 1.1 0.0 41.8 0.0 0.0
Hypoesthesia 23.5 3.1 0.0 26.9 1.9 0.0 5.4 0.0 0.0 5.2 0.0 0.0
Mouth ulceration 23.0 1.0 0.0 10.6 0.0 0.0 5.4 0.7 0.0 1.5 0.0 0.0
Decreased appetite 22.4 1.0 0.0 16.3 0.0 0.0 23.9 1.4 0.0 13.4 0.0 0.0
Myalgia 22.4 0.0 0.0 25.0 1.0 0.0 12.0 0.0 0.0 14.2 0.0 0.0
Neutrophil count
decreased
21.9 11.2 3.6 20.2 12.5 1.9 0.4 0.4 0.0 1.5 0.0 0.0
Headache 20.9 1.0 0.0 18.3 1.9 0.0 33.0 0.4 0.0 37.3 0.0 0.0
Leukopenia 20.4 8.7 0.5 14.4 5.8 1.0 11.6 4.0 0.4 6.7 3.0 0.0
Neurotoxicity 19.9 0.0 0.0 22.1 1.0 0.0 0.4 0.0 0.0 0.7 0.0 0.0
Insomnia 19.9 0.0 0.0 11.5 0.0 0.0 13.8 0.0 0.0 20.1 0.0 0.0
Vomiting 19.4 1.0 0.0 20.2 1.9 0.0 30.1 1.1 0.0 25.4 3.0 0.0
Dizziness 18.9 2.0 0.5 15.4 0.0 0.0 13.4 0.0 0.0 14.9 1.5 0.0
Weight decreased 18.9 0.5 0.0 4.8 0.0 0.0 22.5 2.2 0.0 5.2 0.0 0.0
AST increased 18.4 2.6 0.0 14.4 3.8 0.0 13.8 4.0 0.7 9.0 0.7 0.7
Dyspnea 17.3 2.0 0.0 1.0 0.0 0.0 29.3 4.3 0.7 17.2 1.5 0.0
Constipation 16.3 0.0 0.0 18.3 0.0 0.0 25.0 0.0 0.0 23.1 0.0 0.0
Peripheral sensory
neuropathy
15.8 0.5 0.0 18.3 0.0 0.0 11.6 0.7 0.0 12.7 1.5 0.0
Pruritus 15.8 0.5 0.0 8.7 0.0 0.0 12.0 0.4 0.0 11.2 0.0 0.0
WBC count decreased 15.3 9.7 0.5 12.5 7.7 0.0 1.1 0.7 0.0 0.7 0.0 0.0
Oropharyngeal pain 15.3 0.0 0.0 11.5 0.0 0.0 15.9 0.0 0.0 14.2 0.0 0.0
Arthralgia 13.8 0.0 0.0 11.5 0.0 0.0 19.2 1.4 0.0 21.6 1.5 0.0
Anemia 13.3 5.6 1.0 7.7 1.9 0.0 43.5 10.5 1.4 22.4 3.0 0.0
Hypercholesterolemia 12.8 0.5 0.0 7.7 0.0 0.0 22.5 1.4 0.0 11.2 0.0 0.0
Neuropathy peripheral 12.8 0.5 0.0 15.4 3.8 0.0 40.2 6.2 0.0 31.3 5.2 0.0
Pneumoniaa 12.2 1.5 1.0 4.8 0.0 0.0 7.6 2.9 0.0 3.7 0.0 0.0
Pneumonitisa 12.2 2.0 0.0 2.9 0.0 0.0 19.2 5.4 1.4 5.2 0.7 0.0
Hyperglycemiaa 11.7 4.6 1.0 1.9 1.0 0.0 14.1 5.8 0.7 8.2 1.5 0.0
Pain in extremity 11.7 0.5 0.0 12.5 0.0 0.0 22.5 1.4 0.4 18.7 0.0 0.0
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population. The pronounced efficacy in some sub-
groups and the higher incidence of hematologic ad-
verse events warrant further investigation. Prospective
trials evaluating PI3K/mTOR inhibitors are warranted,
especially in Asian patients with HER2+, HR–
advanced breast cancer.
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